p21 cyclin inhibitor
Selected indexed studies
- CDK inhibitors: positive and negative regulators of G1-phase progression. (Genes Dev, 1999) [PMID:10385618]
- The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. (Nat Med, 1995) [PMID:7489362]
- The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). (Cell Cycle, 2002) [PMID:12429914]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- CDK inhibitors: positive and negative regulators of G1-phase progression. (1999) pubmed
- The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. (1995) pubmed
- The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). (2002) pubmed
- Cyclin-dependent kinase inhibitor p21 in endometrial carcinoma. (1997) pubmed
- Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. (1997) pubmed
- Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. (1998) pubmed
- Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. (1997) pubmed
- Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. (2001) pubmed
- p21: structure and functions associated with cyclin-CDK binding. (1997) pubmed
- The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. (1993) pubmed